The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, lenacapavir, as a tool in their efforts to fight HIV infections – especially for groups most at risk and in areas where the burden of HIV remains high.

Freda Jones, founder of LOTUS, empowers women living with HIV in Atlanta through a peer-led support group. Peer support is crucial for HIV care.

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection. The recommendation, issued at the International AIDS Conference in Kigali,

Black women make up just 13% of the U.S. female population, yet they account for over 50% of new HIV diagnoses among women, according to the Kaiser Family Foundation (KFF). That means more than half of all women newly diagnosed with HIV in the U.S. are Black — a staggering statistic that reflects deep-rooted inequalities.

Artificial intelligence chatbots could help with the introduction of a twice-yearly shot that can help prevent HIV, experts said at the International AIDS Society conference on HIV science in Rwanda on Monday.

At the IAS 2025 conference in Kigali, Rwanda, Banky Olatosi, M.P.H., M.S., Ph.D., of the University of South Carolina, shed light on how systemic racism and social determinants of health influence HIV diagnoses and care across U.

This story was originally published by The Institute for Public Service Reporting Memphis. Healthcare providers across Tennessee are scrambling to find new funding for HIV prevention following the loss of a critical federal grant.

A new study explores how healthcare providers can effectively implement Apretude for HIV pre-exposure prophylaxis (PrEP) among Black women.

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue speakers at a session at the International AIDS Society meeting.

An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in adults with HIV-1 through 24 weeks, according to a phase IIb study.